Publications by authors named "E De Lucia"
FLT3 mutations are among the most common genetic alterations in acute myeloid leukemia (AML) and are associated with poor prognosis. Significant advancements have been made in developing FLT3 inhibitors (FLT3Is), such as quizartinib, which have improved treatment outcomes in both newly diagnosed and relapsed/refractory AML. Resistance to FLT3Is remains a major clinical challenge, driven by diverse mechanisms including FLT3 point mutations, cellular escape pathways, and the influence of the bone marrow microenvironment.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates CP symmetry violation in the decay of D^{+} particles into K^{-}K^{+}π^{+} using data from proton-proton collisions at a high energy of 13 TeV.
- A unique model-independent method was employed to analyze the phase-space distributions of D^{+} and D^{-} particles, correcting for any instrumental biases using D_{s}^{+} decays.
- The findings indicate no significant evidence of CP violation, with a p value of 8.1%, and measure specific CP asymmetry observables, marking this study as the most sensitive search of its kind in multibody decays.
Relapsed and refractory multiple myeloma (RRMM) remains a challenging condition despite advances in immunotherapies. Novel bispecific antibodies (BsAbs), including talquetamab, have shown promising efficacy in heavily pretreated patients, even those with triple- and penta-refractory disease. Talquetamab, recently approved by the FDA and EMA, is indicated for patients who have progressed after at least three or four prior lines of therapy (LOTs).
View Article and Find Full Text PDFPARP inhibitors (PARPi) represent a game-changing treatment for patients with ovarian cancer with tumors deficient for the homologous recombination (HR) pathway treated with platinum (Pt)-based therapy. PARPi exert their cytotoxic effect by both trapping PARP1 on the damaged DNA and by restraining its enzymatic activity (PARylation). How PARP1 is recruited and trapped at the DNA damage sites and how resistance to PARPi could be overcome are still matters of investigation.
View Article and Find Full Text PDFArticle Synopsis
- Therapy-related acute promyelocytic leukemia (t-APL) is a rare condition often arising from treatments like alkylating agents or topoisomerase II inhibitors.
- The report details three cases of t-APL at Cosenza Hospital, each requiring unique treatments following different cancer therapies.
- Notable outcomes include a complete remission in one patient treated with ATRA, while another faced severe complications but also achieved remission; the third patient, however, sadly died due to complications during treatment.